

FIFTEENTH ANNUAL

Markesbery Symposium on Aging and Dementia

Community Session November 1, 2025 9:00am - 12:00pm





On behalf of the Sanders-Brown Center on Aging, our philanthropy council, and the symposium planning committee, I am pleased to welcome you to the 15th annual "Markesbery Symposium on Aging and Dementia."

The symposium is named in honor and memory of the late William R. Markesbery, MD, founding director of the Sanders-Brown Center on Aging and Alzheimer's Disease Research Center at the University of Kentucky. Dr. Markesbery's legacy of groundbreaking research at the Center on Aging has formed the bedrock for our quest to understand and treat Alzheimer's disease and to improve the quality of life of the elderly. We have no doubt that Dr. Bill Markesbery's work will live on for generations to come as we continue the work he started here four decades ago.

In the community session today you will have the opportunity to hear clinicians and researchers from the University of Kentucky and other institutions share current findings, trends, and latest updates on strategies to maintain optimal brain health as we age.

We are honored that so many of you have chosen to join us in seeking to expand our knowledge and friendships. I hope the symposium will be both scientifically rewarding and enjoyable.

Sincerely,

Linda J. Van Eldik, Ph.D.

Director

Sanders-Brown Center on Aging & Alzheimer's Disease Research Center

Symposium Planning Committee:

unda Jo Van Eldik

Linda Van Eldik, PhD Josh M. Morganti, PhD Beverly Baesler April Stauffer Steve Estus, PhD Elizabeth Rhodus, PhD Laura Clewett Beth Wells

Anika Hartz, PhD Frederick Schmitt, PhD Derrick Hord Charlotte Wood

Daniel Lee, PhD Heather Nichols



2025 Markesbery Symposium, Community Session Saturday, November 1, 2025

8:00am	Registration and Continental Breakfast
9:00am	Welcome Linda Van Eldik, PhD, Director, Sanders-Brown Center on Aging & Alzheimer's Disease Research Center (ADRC), University of Kentucky
9:05am	Campaign for Sanders-Brown Beth Wells, Director of Philanthropy, UK HealthCare
9:15am	Dementia and the Aging Brain; Pathology, Risk, and Keeping Memories Alive Julie Schneider, MD, Professor, Departments of Pathology and Neurologica Sciences; Director, Alzheimer's Disease Research Center, Rush University
9:50am	21st Century Breakthroughs in the Diagnosis and Treatment of Alzheimer's and Related Disorders Greg Jicha, MD, PhD, Professor, Neurology; Director of Clinical Core, University of Kentucky ADRC
10:10am	Presentation from Lee Edgerton, Participant Advisory Board
10:20am	Coffee Break
10:35am	The Case for Public Trust in Alzheimer's Research Erin Abner, PhD, Professor and Chair, Department of Epidemiology and Environmental Health, University of Kentucky
10:55am	The Road to Personalized Medicine for Alzheimer's Disease and Related Dementias Andrew Saykin, PsyD, Director, Center for Neuroimaging and Indiana Alzheimer's Disease Research Center; Professor, Departments of Radiology Psychiatry, Neurology and Medical & Molecular Genetics, Indiana University School of Medicine
11:30am	Panel Discussion moderated by Daniel C. Lee, PhD and Steven Estus, PhD Julie Schneider, MD Andrew Saykin, PsyD Greg Jicha, MD, PhD Erin Abner, PhD Sarah Hatch, MSW, CSW
11:55 am	Closing Remarks – Linda Van Eldik, PhD

Please remember to complete the satisfaction survey for this program.



YOU CAN MAKE A DIFFERENCE IN OUR FIGHT AGAINST DEMENTIA

Sanders-Brown is recognized around the world as a leader in the fight against Alzheimer's and other age-related dementias.

You can help continue that legacy for you, your loved ones, and for generations to come.



DONATE NOW

Scan the QR code with your smartphone

Questions?

Contact Beth Wells, Director of Philanthropy beth.wells@uky.edu | 859-319-6886



"Dementia and the Aging Brain; Pathology, Risk, and Keeping Memories Alive"

Dr. Julie Schneider, MD, Professor, Departments of Pathology and Neurological Sciences; Director, Alzheimer's Disease Research Center, Rush University

Julie Schneider, MD, is Director at the Rush Alzheimer's Disease Research

Center at Rush University in Chicago where she is the Deborah R. and Edgar D. Jannotta Presidential Professor of Pathology and Neurological Sciences. She completed her Neurology residency at the University of Chicago and Neuropathology fellowship at Emory University. Dr. Schneider leads clinicopathologic work for multiple studies including the Rush Religious Orders Study and Memory and Aging Project. Dr. Schneider's research explores the relationship between neuropathology and age-related cognitive decline, with particular emphasis on risk factor discovery, biomarker development, and prevention/treatment strategies. Her research expertise includes Alzheimer's disease, Limbic-predominant Age-related TDP-43 Encephalopathy (LATE), Vascular and Mixed Dementias. She is a member of the National Advisory Council on Aging and has an extensive record of publications.

With apologies: Sanders-Brown is unable to share speaker PowerPoint presentations.







"The Road to Personalized Medicine for Alzheimer's Disease and Related Dementias"

Dr. Andrew Saykin, PsyD, Director, Center for Neuroimaging and Indiana Alzheimer's Disease Research Center; Professor, Department of Radiology, Psychiatry, Neurology and Medical & Molecular Genetics, Indiana University School of Medicine

Andrew Saykin, PsyD, is Director of the

Indiana Alzheimer's Disease Research Center at Indiana University. He is also the Raymond C. Beeler Professor of Radiology and Professor of Medical and Molecular Genetics, Neurology and Psychiatry. In addition, he leads the Genetics Core of the Alzheimer's Disease Neuroimaging Initiative. Dr. Saykin's research focuses on precision medicine for early Alzheimer's disease detection and for identification of disease mechanisms that may lead to potential therapeutic targets. Dr. Saykin uses integrative analysis strategies to study the relationship among clinical phenotypes, genetic susceptibility, and molecular signatures in Alzheimer's disease and other complex diseases. He participates in multiple training programs where he is committed to fostering the next generation of translational researchers. He is founding Editor-in-Chief of Brain Imaging and Behavior and has an extensive publication record.

With apologies: Sanders-Brown is unable to share speaker PowerPoint presentations.





"21st Century Breakthroughs in the Diagnosis and Treatment of Alzheimer's and Related Disorders"

Dr. Greg Jicha, MD, PhD University of Kentucky

Dr. Jicha is a Professor and Vice Chair for Academic Affairs in the Department of Neurology and an Associate Director of Sanders-Brown Center on Aging. Dr. Jicha holds the Robert T. & Nyles Y. McCowan Endowed Chair in Alzheimer's Research and leads the Clinical Core of the UK NIA-funded Alzheimer's Disease Research

Center. He also serves as the Medical Director of KY Telecare and directs the Telemedicine Cognitive Clinic at UK, designed to reach out to rural populations across Kentucky for both clinical and research- related activities in the area of AD and related disorders.

He is the principal investigator at UK for the National Alzheimer's Disease Cooperative Study Group, the Alzheimer's Clinical Trial Consortium, and serves on the Clinical Task Force and Steering Committee for the National Institute of Aging Alzheimer's Disease Research Center Program. His current research interests are preclinical disease states of dementia, mild cognitive impairment, vascular contributions to dementia, and clinical trials of disease modifying therapies for degenerative dementias.



"The Case for Public Trust in Alzheimer's Research"

Erin Abner, PhD University of Kentucky


Dr. Erin Abner is a Professor and Chair of the Department of Epidemiology & Environmental Health with joint appointments in the UK Sanders-Brown Center on Aging and the Department of Biostatistics, at the University of Kentucky. Dr. Abner joined the College as an assistant professor in 2013. She is the author and

co-author of more than 100 peer-reviewed publications. Dr. Abner is currently an MPI or co-investigator on multiple NIH-funded grants, including the NIH/NIA Alzheimer's Disease Research Center at the UK Sanders-Brown Center on Aging, where she is the Co-Leader of the Data Management and Statistics Core. Dr. Abner's current research is focused on assessing how medical conditions like hypertension and diabetes are related to cognitive impairment and neuropathology.





Sanders-Brown Center on Aging



The Sanders-Brown Center on Aging (SBCoA

was established in 1979, and received funding as one of the original ten National Institutes of Health Alzheimer's Disease Centers in 1985. Internationally acclaimed, the SBCoA is recognized for its contributions to the fight against brain diseases that are associated with aging.

Our vision: The University of Kentucky Sanders-Brown Center on Aging will be recognized locally and nationally as a premier, vitally productive and innovative aging center that effectively translates research findings into interventions and information that will benefit older adults.

ALZHEIMER'S DISEASE FACTS

Normal Age-Related Memory Changes

- Missing a monthly payment
- Forgetting which day it is and remembering later
- Sometimes forgetting which word to use
- Losing things from time

Warning Signs of Dementia

- Poor judgment and decision making
- Inability to manage a budget
- Losing track of the date or the season
- Misplacing things and being unable to retrace steps



More than 100 faculty and staff pursuing the following areas of research:

- Basic and clinical research in Alzheimer's disease
- Neurodegenerative disorders
- · Risk factors for dementia
- · Healthy brain aging

A global pioneer in Alzheimer's disease research, the Center has over forty years of published work and 800 study volunteers (some with the disease and some without). These individuals are studied over time and will donate their brains upon death. Our cutting-edge research focuses on identifying problems as early as possible, before memory loss develops, so that Alzheimer's disease can be prevented or delayed.

The ultimate goal of the Center on Aging is to catalyze innovative and outstanding brain research, while ensuring a more rapid rate of progress toward new therapies, so that our volunteers, patients and caregivers become the beneficiaries of our advances in knowledge.

Unless science finds a way to slow the progression of this devastating disease, the United States will see 12.7 million Americans by 2050. In addition to the direct impact on the person with Alzheimer's, the disease also affects the lives of family members and friends.



The Center is directed by Linda J. Van Eldik, PhD, Professor, Department of Neuroscience, Director, Alzheimer's Disease Research Center and Co-Director, Kentucky Neuroscience Institute

Photo Credit Aaron Conway



Alzheimer's disease is the most common cause of dementia, accounting for an estimated 60 to 80 percent of cases.


Most individuals also have the brain changes of one or more other causes of dementia. This is called mixed pathologies, and if recognized during life is called mixed dementia.

More than 50% of people diagnosed with Alzheimer's dementia who were studied at Alzheimer's Disease Research Centers had mixed dementia.


Mixed dementia is most common in people age 85 or older.

As of 2025, approximately 80,500 persons in Kentucky are living with Alzheimer's disease.

From the 2025 Alzheimer's Association Facts & Figures publication.




WILLIAM R. MARKESBERY, MD (1932-2010)



The Markesbery Symposium on Aging and Dementia is named in honor of William R. Markesbery, MD, a gifted scientist and internationally recognized neurologist and neuropathologist. Dr. Markesbery's creativity and commitment to aging research provided the impetus for the University of Kentucky to establish the Sanders- Brown Center on Aging in 1979 and name him as the first director. He held that position until his death in January 2010.



In 1985, Bill Markesbery became the director of the Alzheimer's Disease Research Center, one of the original 10 National Institute on Aging (NIA)-funded centers in the United States, with a primary focus on neuropathology. After more than 40 years, the Alzheimer's Disease Center continues to be funded by NIA, a remarkable achievement that demonstrates the strength and caliber of this program. During his academic career, Dr. Markesbery published more than 400 scientific papers and was one of the world's leading experts on Alzheimer's disease and oxidative stress. He will always be remembered as a compassionate and caring physician, a brilliant researcher, and an inspirational leader.





The BenfoTeam clinical research trial aims to increase the amount of thiamine (Vitamin B1) in the brain to slow cognitive decline in people with Mild Cognitive Impairment and mild Alzheimer's Disease

The trial is designed for people who are age 50-89, and are experiencing significant memory concerns, or who have already been diagnosed with Mild Cognitive Impairment (MCI) or mild Alzheimer's disease (AD). This stage of the disease, MCI through mild AD, is also known as early AD.



Basic Eligibility Criteria

- Aged 50-89
- Diagnosed with early AD, Mild Cognitive Impairment (MCI) due to AD or probable Mild AD
- Stable on current FDA-approved acetylcholinesterase inhibitors (with or without memantine) for at least three months prior to screening
- Living in the community (not in a long-term care nursing facility)
- Willing to participate in the BenfoTeam study for up to 18 months (plus screening)

What happens during the BenfoTeam Study?

Trial participation will take up to 18 months. Potential participants will first go through the screening process to see if they are eligible to take part in the clinical trial. Half of the participants are given the study drug, benfotiamine, and half are given an inactive pill (called a placebo) to take twice daily.

Screening includes: Memory and thinking tests, blood tests, EKGs (a look at your heart rhythms), and MRI scans (a picture of your brain that shows changes related to AD).

For more information or to volunteer, please contact:

Melanie Elam

Phone: 859-323-1331

Email: Melanie.Elam@uky.edu


www.BenfoTeam.org

Be BRIGHT



Behavioral & Biomedical Research In General Health & Thinking

- This program can help you track your memory & thinking over time as you age!
- > It can also help inform you of other research opportunities you might be eligible for!



Why might you want to consider joining Be BRIGHT?

- √ You have a family history of dementia or have risk factors for dementia you want to address
- ✓ You are looking for a way to stay informed and help move healthy aging research forward
- ✓ Participation is so easy with just a 30-minute telephone evaluation every year that assesses your dementia risk
- ✓ Free brain health reports and VIP status for our many brain health events at your fingertips at no cost to you!
- ✓ No travel to Lexington, so you can engage from anywhere in Kentucky and our surrounding states at your leisure



What will you be asked to do if you join?

- ✓ Answer questions about your medical health, lifestyle, memory concerns, and take a brief memory test every year
- There are no other obligations, and we will protect your privacy and confidentiality completely

Your participation will make a difference!

- ✓ We have learned that not everyone can travel to Lexington and do everything our research program asks like MRI/PET scans & autopsy/brain donation
- √ This prevents us from understanding memory & thinking changes in everyone
- ✓ Be BRIGHT is designed to help us make sure our research helps ALL OF US!



- ✓ Be BRIGHT is completely free-of-charge but you must be age 50 or older, have telephone or internet access and live within a 5-hour radius of Lexington, KY
- \checkmark To get started now scan the QR Code to the left \boxtimes
- √ Or call us now at (859) 323-5550 to learn more!





A new Alzheimer's research study is enrolling participants

The ONO-2020-02 Study is looking at an investigational drug for people with mild to moderate Alzheimer's disease.

The investigational drug is aimed at helping people who are living with Alzheimer's disease with their symptoms. Specifically, the study is looking to see:

- · how safe the investigational drug is
- · what side effects it causes
- how well the body processes it
- if it might help to improve Alzheimer's symptoms, such as memory loss.

You or someone you care for may be able to take part if the person with Alzheimer's:

- is 55–85 years of age,
- · has mild to moderate Alzheimer's, and
- has a care partner who also consents to participate. The care partner will attend study visits with the participant.

The study will last for up to 9 months. There will be 10 study center visits.

Want to know more?

If you are interested in learning more about the ONO-2020-02 Study, please contact:

> Melanie Elam at 859-323-1331 or Laura Clewett at 859-218-8097

articip nt Flyer, 13 Mar 2025 [V01 USA(en)]

ONO-2020-02

CAREGIVER RESEARCH

STUDY

ONLY ONE WEEK COMMITMENT

If you care for someone with dementia, we'd love to talk with you about this one week study to better understand the physiological effects of caregiving

Participation will be compensated!



YOU MAY BE ELIGIBLE IF...

- You care for someone with dementia who is between 60-99 years old
- The person with dementia lives at home
- You and your care partner speak English
- You are comfortable using electronic devices

For more information, please:

SCAN



OR VISIT THE WEBSITE bit.ly/3NDMUrd



An Equal Opportunity University

QUESTIONS?


PLEASE CONTACT: Dr. Elizabeth Rhodus

859-257-5562 | EngagingAging@uky.edu

Notes

Notes

-	



Your opinion matters.

Please take a few minutes to complete the evaluation for this program, so that we may improve future programs.

FOLLOW US ON SOCIAL MEDIA





















Sanders-Brown Building | Lexington, Kentucky 40536-0230 (859) 323-5550 | https://medicine.uky.edu/centers/sbcoa/